The beat-and-raise quarter with accelerated buybacks is a clear positive. Monitor the Q4 print for continued execution on OneOncology integration and margin expansion in U.S. Healthcare Solutions. The accelerated $1B buyback signals management confidence in cash flow generation.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 5 $317.22entry
- T+1 · 3mo ago +2.46%α +2.62% · $325.01
- T+5 · 3mo ago −0.96%α −1.31% · $314.17
- T+20 · 3mo ago +6.03%α +6.64% · $336.36
- T+60 · 18d ago +3.48%α +3.28% · $328.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cencora reported fiscal Q3 2026 revenue of $84.8B (+5.1% YoY) and adjusted diluted EPS of $4.48, beating consensus estimates of $4.35 by 3.0%. The company raised its full-year adjusted EPS guidance to $17.75-$17.95 and repurchased $1B in shares during the quarter, signaling strong operational momentum and capital return to shareholders.
Key Financial Metrics
Key Facts
- Revenue of $84.8B, up 5.1% YoY, beating $84.15B consensus
- Adjusted diluted EPS of $4.48, up 12.0% YoY, beating $4.35 consensus
- FY2026 adjusted EPS guidance raised to $17.75-$17.95 from $17.70-$17.90
- Repurchased $1B in shares during Q3, accelerating the prior $1B target from end of calendar 2026
- U.S. Healthcare Solutions segment operating income up 15.9% YoY, driven by OneOncology acquisition
- International Healthcare Solutions segment operating income up 20.8% YoY
- GAAP diluted EPS of $3.94, up 11.9% YoY
- Quarterly dividend maintained at $0.60 per share
Financial Impact
Revenue beat consensus by ~$650M; adjusted EPS beat by $0.13 (3.0%); FY guidance raised by $0.05 at midpoint
Risk Factors
- Higher interest expense ($140.7M, +72% YoY) from debt financing of OneOncology
- GLP-1 mix shift continues to pressure gross margins
- Opioid litigation liability remains at $3.8B on balance sheet
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140859-26-000032 |
| Document: abc-20260805.htm | 0001140859-26-000032 |
| Document: 0001140859-26-000032-index-headers.html | 0001140859-26-000032 |
| Document: 0001140859-26-000032-index.html | 0001140859-26-000032 |
| Document: 0001140859-26-000032.txt | 0001140859-26-000032 |
| 8-K Data (Synthetic) | 0001140859-26-000032 |
Track record
12 reports on COR
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: −0.32% at T+1 after the Feb 28, 2026 report. 0 of 3 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Neutral 2/10 Entry $354.00 to $339.68 Now $357.68 +1.04% ▼ −4.05% +0.36% vs SPY
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $354.00 to $339.68 Now $357.68 +1.04% ▼ −4.05% +0.36% vs SPY
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $340.43 to $338.48 Now $357.68 +5.07% ▼ −0.57% +0.61% vs SPY
- Oct 20, 202627d ago Institutional Cluster Mixed 3/10 Entry $340.43 to $338.48 Now $357.68 +5.07% ▼ −0.57% +0.61% vs SPY
- Sep 25, 20267w ago 8-K Neutral 2/10 Entry $306.92 to $303.81 Now $357.68 +16.54% ▼ −1.01% −0.27% vs SPY
- Aug 21, 202612w ago Institutional Cluster Mixed 6/10 Entry $318.04 to $323.77 Now $357.68 +12.46% ▲ +1.80% +2.10% vs SPY
- Aug 5, 202614w ago 8-K Neutral 3/10 Entry $317.22 to $325.01 Now $357.68 +12.75% ▲ +2.46% +2.62% vs SPY
- Aug 5, 202614w ago 8-K Bullish 6/10 Viewing Entry $317.22 to $325.01 Now $357.68 +12.75% ▲ +2.46% +2.62% vs SPY
- Jun 15, 202621w ago 8-K Neutral 2/10 Entry $281.46 to $277.09 Now $357.68 +27.08% ▼ −1.55% −0.30% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Entry $264.69 to $264.84 Now $357.68 +35.13% ▲ +0.06% −0.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers